Pacira BioSciences, Inc.
PCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframePacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. Valued at $1.45B, PCRX is a small-cap name in its sector. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
Market Cap
$1.45B
Beta
0.25
P/E (TTM)
104.06
P/E (Fwd)
10.53
EPS (TTM)
$0.35
EPS (Fwd)
$3.46
ROE
2.1%
ROA
1.5%
Cash
$251.0M
Total Debt
$412.1M
Free CF
$98.3M
52W Change
70.8%
Annual Financials
Cash vs Debt
Where PCRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PCRX finished 45.24% above its 150-day moving average ($25.02) and 49.61% above its 200-day moving average ($24.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PCRX overbought or oversold?
At the October 20, 2026 close, PCRX's RSI(14) was 90.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pacira BioSciences, Inc. carries $412.1M in total debt against $251.0M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $98.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 2.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $666.8M (2022) to $726.4M (2025).
PCRX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing PCRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.